• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PHE drug development to transfer to new state-owned company

PHE drug development to transfer to new state-owned company

July 10, 2015
CenterWatch Staff

Public Health England will transfer its drug development and production to a new company, Porton Biopharma. The transfer of Public Health England’s (PHE’s) clinical drug development and production capability into a stand-alone, state-owned biopharmaceutical limited company has been approved by the Secretary of State for Health.

Clinical drug production and development has taken place at Porton, near Salisbury, Wiltshire since the 1970s and last year this generated revenues of more than $68.2 million.

The new company, Porton Biopharma, wholly owned by the Secretary of State for Health, will employ over 200 people at the Porton site and now will be better placed to develop further business. The future success and revenue growth of Porton Biopharma will provide PHE with an income dividend which will be ploughed back into the delivery of its priorities.

Dr. Roger Hinton, managing director, said, “Working as part of Public Health England, and prior to that in the Health Protection Agency, has enabled us to go through all the early stages of our development in a carefully managed and controlled manner. Now as a stand-alone company, we can better compete in the biopharmaceutical market and shape our own future, pursue more opportunities and more rapidly respond to changes in global drug markets.

The company manufactures the leukaemia drug Erwinase as well as the only U.K. licensed Anthrax vaccine. It also produces a wide range of clinical materials for clients and its Containment Level 3 capability enables it to produce bespoke low volume, high toxicity bacterial products and provides commercial services to overseas governments including the U.S. Department of Defense and the U.S. National Institutes of Health.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing